Dr Lal PathLabs to buy 70% of SN Genelab in genomics push
Dr Lal PathLabs has approved the acquisition of a 70% stake in Gujarat-based genomics diagnostics provider SN Genelab for up to ₹168 crore in cash, with a performance-linked earn-out capped at ₹31.5 crore. The deal is expected to close by November 30, 2026.
What happened
Dr. Lal PathLabs · Dr Lal PathLabs approved acquisition of a 70% stake in Gujarat-based genomics diagnostics provider SN Genelab for up to ₹168 crore cash plus
Key facts
- 70% stake
- Up to ₹168 crore cash consideration
- ₹31.5 crore performance-linked earn-out cap
- SN Genelab FY26 turnover: ₹57.96 crore
- SN Genelab FY25 turnover: ₹53.36 crore
- SN Genelab FY24 turnover: ₹43.27 crore
Why this matters
The acquisition signals a targeted move into high-complexity genomics diagnostics, combining a regional specialist’s expertise with Dr Lal PathLabs’ distribution, brand and patient access.
What to watch
- Completion timing and final cash consideration versus the stated ₹168 crore upfront cap and ₹31.5 crore earn-out cap.
- SN Genelab revenue growth, EBITDA trajectory and whether FY26 turnover growth sustains after acquisition closing.
- Retention of founders, pathologists, molecular biologists, bioinformaticians and key referring clinicians.
- Expansion of genomics test availability across Dr Lal's network, including test volumes, turnaround time and share of samples referred from outside Gujarat.
- Regulatory, accreditation and data-privacy compliance for genetic testing, sample handling and genomic-data reporting.
- Changes in specialty diagnostics mix, average realization per test and margin commentary in Dr Lal PathLabs' post-close earnings.
- Competitive actions from Metropolis, SRL, Thyrocare, hospital chains and specialized genomics laboratories.
- Roll out SN Genelab's genomics panels through Dr Lal PathLabs' collection-center and B2B clinician network, initially in Gujarat and major metros.
- Integrate laboratory information systems, sample logistics, quality controls and reporting workflows while retaining key genomics scientists and medical specialists.
- Bundle genomic testing with oncology, prenatal, infertility, preventive-health and rare-disease diagnostic pathways to raise specialty-test attach rates.
- Use the performance-linked earn-out to prioritize revenue, turnaround-time, accreditation and profitability milestones before committing additional expansion capital.
- Evaluate further bolt-on acquisitions or partnerships in molecular diagnostics, bioinformatics, digital genetic counseling and hospital oncology networks if demand validates the platform strategy.